These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23298762)

  • 21. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
    Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
    Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for Dietary Fibre Modification in the Recovery and Prevention of Reoccurrence of Acute, Uncomplicated Diverticulitis: A Systematic Literature Review.
    Dahl C; Crichton M; Jenkins J; Nucera R; Mahoney S; Marx W; Marshall S
    Nutrients; 2018 Jan; 10(2):. PubMed ID: 29382074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    Strate LL; Modi R; Cohen E; Spiegel BM
    Am J Gastroenterol; 2012 Oct; 107(10):1486-93. PubMed ID: 22777341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic diverticular diseases. Rifaximin reduces symptoms and complications].
    MMW Fortschr Med; 2010 May; 152(21):98-9. PubMed ID: 20608137
    [No Abstract]   [Full Text] [Related]  

  • 25. Preventing diverticulitis recurrence by selecting the right therapy for a complex disease.
    Tursi A; Danese S
    Gastroenterology; 2014 Oct; 147(4):733-6. PubMed ID: 25167986
    [No Abstract]   [Full Text] [Related]  

  • 26. Interaction between rifaximin and dietary fibre in patients with diverticular disease.
    D'Incà R; Pomerri F; Vettorato MG; Dal Pont E; Di Leo V; Ferronato A; Medici V; Sturniolo GC
    Aliment Pharmacol Ther; 2007 Apr; 25(7):771-9. PubMed ID: 17373915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis.
    Festa V; Spila Alegiani S; Chiesara F; Moretti A; Bianchi M; Dezi A; Traversa G; Koch M
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1397-1404. PubMed ID: 28387885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.
    Gionchetti P; Rizzello F; Ferrieri A; Venturi A; Brignola C; Ferretti M; Peruzzo S; Miglioli M; Campieri M
    Dig Dis Sci; 1999 Jun; 44(6):1220-1. PubMed ID: 10389700
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of colonic diverticular disease.
    Frieri G; Pimpo MT; Scarpignato C
    Digestion; 2006; 73 Suppl 1():58-66. PubMed ID: 16498253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing diverticulitis: mesalamine may still be indicated in the decision.
    Floch MH
    Gastroenterology; 2015 Apr; 148(4):856. PubMed ID: 25726738
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension.
    Dughera L; Serra AM; Battaglia E; Tibaudi D; Navino M; Emanuelli G
    Minerva Gastroenterol Dietol; 2004 Jun; 50(2):149-53. PubMed ID: 15722985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifaximin therapy in minimal hepatic encephalopathy cirrhotics.
    Zullo A; Hassan C; Lorenzetti R
    Am J Gastroenterol; 2011 Nov; 106(11):2041; author reply 2041-2. PubMed ID: 22056578
    [No Abstract]   [Full Text] [Related]  

  • 34. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins.
    Cacciottolo TM; Kingdon A; Alexander GJ
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1765. PubMed ID: 24703862
    [No Abstract]   [Full Text] [Related]  

  • 35. [Functional and motor gastrointestinal disorders].
    Mearin F; Rey E; Balboa A
    Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():3-12. PubMed ID: 26520191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rifaximin treatment in hepatic encephalopathy.
    Wang CC; Kao JH
    N Engl J Med; 2010 Jun; 362(25):2423; author reply 2424-5. PubMed ID: 20573932
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy.
    Kowdley KV; Burman BE
    Ann Intern Med; 2013 Oct; 159(8):JC8. PubMed ID: 24126669
    [No Abstract]   [Full Text] [Related]  

  • 39. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
    Congly SE; Leise MD
    Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864
    [No Abstract]   [Full Text] [Related]  

  • 40. Rifaximin treatment in hepatic encephalopathy.
    Sharma P; Sharma BC
    N Engl J Med; 2010 Jun; 362(25):2423-4; author reply 2424-5. PubMed ID: 20578274
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.